ImmTune Therapies
Develops a targeted nanoparticle delivery platform for in‑vivo genetic engineering of patient cells. The technology is designed to transport nucleic acid payloads (DNA, mRNA) and programmable targeting ligands to specific cell types (first focus: T cells for CAR gene delivery) with the aim of enabling scalable, lower‑complexity cell and gene therapies and accelerating preclinical-to-clinical translation through partnerships.
Industries
biotechnology
health-care
manufacturing
pharmaceutical
therapeutics
Nr. of Employees
small (1-50)
Products
In vivo CAR gene delivery to T cells (preclinical)
A nanoparticle‑based approach to deliver CAR genes to T cells directly in vivo to generate CAR‑T cells without ex vivo manufacturing.
In vivo CAR gene delivery to T cells (preclinical)
A nanoparticle‑based approach to deliver CAR genes to T cells directly in vivo to generate CAR‑T cells without ex vivo manufacturing.
Services
Collaborative preclinical delivery development
Partnership engagements to develop targeted nanoparticle delivery solutions and co‑develop payload/delivery combinations for specific therapeutic goals.
Collaborative preclinical delivery development
Partnership engagements to develop targeted nanoparticle delivery solutions and co‑develop payload/delivery combinations for specific therapeutic goals.
Expertise Areas
- In vivo nanoparticle delivery
- Gene delivery and genetic engineering
- Nanoparticle formulation and functionalisation
- Formulation stability and lyophilisation
Key Technologies
- Targeted nanoparticle vectors
- mRNA and DNA delivery
- Ligand functionalisation for cell targeting
- Lyophilisation and stability testing